Business Context and Reporting Period
This Form 8-K Current Report, filed on April 27, 2021, by Karyopharm Therapeutics Inc. (KPTI), discloses significant changes in executive leadership effective May 3, 2021. The filing details the appointment of a new Chief Executive Officer and the resignation of the previous CEO and President, alongside updated employment agreements for departing executives.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation and employment terms.
- New CEO Base Salary: $670,000 annually.
- New CEO Sign-on Bonus: $700,000 total, payable in three installments ($300,000, $200,000, $200,000) contingent on continued employment.
- New CEO Equity Grant: 559,800 stock options and 373,200 restricted stock units (RSUs).
- Former CEO (Dr. Kauffman) New Role Salary: $388,125 annually as Senior Clinical Advisor.
- Former President (Dr. Shacham) Salary: $499,905 for remainder of 2021; reducing to $300,000 effective January 1, 2022.
Material Changes Versus Prior Period
The primary material change is the complete turnover of the Company's top operational leadership:
- Appointment: Richard Paulson appointed President and CEO, effective May 3, 2021. He succeeds Michael G. Kauffman and Sharon Shacham.
- Resignations: Michael G. Kauffman resigned as CEO and Sharon Shacham resigned as President, both effective May 3, 2021.
- Role Transitions: Dr. Kauffman transitions to Senior Clinical Advisor. Dr. Shacham remains Chief Scientific Officer and Chair of the Scientific Advisory Board but will cease direct management responsibilities on January 1, 2022.
- Board Changes: Mr. Paulson will no longer serve on the Audit Committee; Chen Schor was appointed to replace him.
Guidance, Outlook, and Risks
The filing contains no financial guidance, market outlook, or discussion of general business risks. However, it outlines specific contractual contingencies and risks related to executive retention and severance:
- Clawback Provisions: Mr. Paulson's sign-on bonus is subject to repayment (100% or 50%) if he resigns without "Good Reason" or is terminated for "Cause" within specific timeframes relative to the milestone dates.
- Severance Obligations: Significant severance packages are triggered by termination without Cause or resignation for Good Reason.
- Mr. Paulson: 18 months salary continuation, unpaid milestone payments, and pro-rated bonus. In a Change in Control scenario, the bonus increases to 150% of target.
- Dr. Kauffman: Salary continuation at $646,875 per annum (if terminated before May 3, 2023) or a lump sum of $323,500 (if terminated after).
- Dr. Shacham: Salary continuation at $499,905 per annum (if terminated before Jan 1, 2024) or a lump sum of $150,000 (if terminated after).
- Equity Surrender: Both Dr. Kauffman and Dr. Shacham surrendered rights to 290,000 shares of Common Stock options each as part of their new agreements.
Investor Verification Checklist
- Verify the effective date of the leadership transition (May 3, 2021) and the immediate impact on strategic direction.
- Review the specific vesting schedules for Mr. Paulson's 559,800 stock options and 373,200 RSUs to assess long-term retention incentives.
- Assess the total potential cash outflow for severance packages under various termination scenarios for all three executives.
- Confirm the reduction in Dr. Shacham's direct management responsibilities starting January 1, 2022, and its potential impact on scientific operations.
- Check the composition of the Audit Committee following Mr. Paulson's departure from that role.